Ali Khademhosseini is the CEO of the Terasaki Institute for Biomedical Innovation. Formerly, he was Levi Knight Professor of Bioengineering, Chemical Engineering, and Radiology at the University of California-Los Angeles (UCLA). He was the Founding Director of the Centre for Minimally Invasive Therapeutics at UCLA. He joined UCLA starting from Nov. 2017 from Harvard University where he was a Professor at Harvard Medical School (HMS) and faculty at the Harvard-MIT’s Division of Health Sciences and Technology (HST), Brigham and Women’s Hospital (BWH) as well as an associate faculty at the Wyss Institute for Biologically Inspired Engineering. At Harvard University, he directed the Biomaterials Innovation Research Centre (BIRC) a leading initiative in making engineered biomedical materials. He has edited multiple books/journal special issues and is an author on >650 peer-reviewed journal articles, editorials and review papers, >70 book chapters/edited books, and >20 patent/disclosure applications. His work has been published in leading journals and routinely highlighted in international media. He has been cited >64,800 times and has an H-index of 131. Also, he has given over 250 invited seminars and keynote lectures. Annually for the past five years, he has been selected by Thomson Reuters as one of the World’s Most Influential Minds as a Highly Cited Researcher.